Professor Blackburn is the inventor of the Sengenics Immunome Protein Array technology. He has more than 35 years background at the highest levels of cutting-edge genomics and proteomics research and development. He invented and developed the Immunome platform at the University of Cambridge. He leads the R&D team and the strategic direction for developing Immunome across novel diverse applications for Human disease screening, diagnostics and therapeutics.
Professor Jonathan Blackburn
Chief Scientific Officer
Dato’ Wong Gian Kui
Dato’ Wong is a Non-Executive Director who was appointed to the Board of Sengenics in March 2011. He was appointed as Managing Director of Insas in 2000, Chief Executive officer/Group Managing Director in 2004, and in 2009 was re-designated to Non-Independent & Non-Executive Director of Insas. Prior to joining Insas, Dato’ Wong worked for Harun, Oh & Wong, a member of Howarth International firm of public accountants in Malaysia from 1981 to 1990 and Stoy Hayward London Chartered Accountants from 1990 to 1991. He has been a member of the Malaysian Institute of Accountants since 1988 and of the Malaysian Institute of Certified Public Accountants since 1985.
Dr Tan Seng Chuan
Dr Tan is a Non-Executive Director who was appointed to the Board of Sengenics in March 2011. He graduated with First Class Honours in Mechanical Engineering from Imperial College, England in 1978 and obtained his Masters and PhD in Engineering Science in 1981 and 1983 respectively from Harvard University, USA. Dr Tan has very wide experience in the IT industry. He has worked on leading edge software and hardware product development with many companies in the global IT industry. He is also Executive Director of Insas and was appointed to the Board of Insas in March 1997.
Amran is currently the CEO of SBI (formerly Soft Bank Investment) Brunei, a private equity fund manager jointly owned by the Ministry of Finance Brunei and SBI Japan. 20 years career in investment banking and private equity investments, including founding shareholder and board member of Al-Rajhi Bank Malaysia. Amran has a First Class Honours degree in Accounting from Edith Cowan University.
Vice President of Investment of SBI (formerly Soft Bank Investment) Brunei. Highly skilled in comparable analysis, financial modelling, corporate finance, due diligence, non-executive directorships, environmental and social governance and investor relations. Rafiuddin has a First Class Honours degree in Finance from Nottingham University and has both ACCA and IFQ professional qualifications.
Dr Arif Anwar
Executive Director and Board Director
Prior to his current role at Sengenics, Dr Arif held progressively senior positions in genomics and bioinformatics companies in Silicon Valley, the UK and most recently in in Asia over a period spanning more than twenty years. He has a prodigious track record of success in conceptualising and commercialising cutting-edge genomics technologies. Out of the five genomics companies he has been involved in, two were acquired, and two went on to successful IPOs. His previous roles include Commercial Director of PhenoCure UK Ltd., a bio-pharmaceutical company he co-founded in Cambridge, UK; Regional Director at DoubleTwist Inc. of Oakland, CA and Regional Manager of Clontech of Palo Alto, CA. He holds a PhD in Molecular Virology & Biochemistry awarded in 1996 by UCL, London and a BSc in Genetics in 1993 from the University of London. Dr Arif has overall responsibility for managing corporate strategy and operations.
Chief Commercial Officer
Johan’s primary role is to devise and roll-out the commercial strategy for the company. He has more than a decade of industry experience working in high-technology and biotechnology companies, initiating medium to large-scale genomics and proteomics research projects, strategic partnerships and collaborations in the United States, Europe and Australasia. Key milestones includes initiating one of the largest de novo plant genome sequencing project in 2007 and collaborations with leading institutions such as Stanford Medical School, Merck and GSK in the USA.